Anti-tumor effects of rivoceranib against canine melanoma and mammary gland tumour in vitro and in vivo mouse xenograft models

BACKGROUND: Rivoceranib, a novel tyrosine kinase inhibitor, exhibits anti-tumour effects by selectively blocking vascular endothelial growth factor receptor-2 (VEGFR2) in cancer cells. Recently, the therapeutic effects of rivoceranib on solid tumours have been elucidated in human patients. However,...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Qiang, Kim, You-Seok, An, Ju-Hyun, Kwon, Jin-Ah, Han, Sang-Hyun, Song, Woo-Jin, Youn, Hwa-Young
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8546947/
https://www.ncbi.nlm.nih.gov/pubmed/34702279
http://dx.doi.org/10.1186/s12917-021-03026-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8546947/
https://www.ncbi.nlm.nih.gov/pubmed/34702279
http://dx.doi.org/10.1186/s12917-021-03026-1

Ejemplares similares